Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation. Am J Gastroenterol 2007 Feb;102(2):449-51 PMID: 17100972

Pubmed ID

17100972

Abstract

A 48-yr-old man with acute myeloid leukemia (AML) required urgent allogeneic hematopoietic stem cell transplantation because of failed attempts to induce remission via chemotherapy. He had an HLA identical donor sister who was hepatitis C virus (HCV) RNA positive. In order to prevent HCV transmission to her brother, the donor was treated with weekly injections of pegylated interferon alfa-2b (150 mug subcutaneously every week) and daily ribavirin (1 g/day) for 5 wk at which time her qualitative polymerase chain reaction (PCR) was negative. Her stem cells were successfully grafted into the recipient. The recipient remained HCV PCR negative after transplant until death from relapsed AML.

Author List

Surapaneni SN, Hari P, Knox J, Daniel J, Saeian K

Authors

Parameswaran Hari MD Chief, Professor in the Medicine department at Medical College of Wisconsin
Kia Saeian MD Professor in the Medicine department at Medical College of Wisconsin




Scopus

2-s2.0-33846547897   12 Citations

MESH terms used to index this publication - Major topics in bold

Administration, Oral
Antiviral Agents
Disease Transmission, Infectious
Drug Therapy, Combination
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Hepacivirus
Hepatitis C
Humans
Injections, Subcutaneous
Interferon-alpha
Leukemia, Myeloid, Acute
Male
Middle Aged
Polyethylene Glycols
Polymerase Chain Reaction
RNA, Viral
Recombinant Proteins
Ribavirin
Transplantation, Homologous
jenkins-FCD Prod-332 f92a19b0ec5e8e1eff783fac390ec127e367c2b5